Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18532541 | 1.00 | CCR5 (0.40) | CCR5KMT2APREPHCRTR1HCRTR2 | |
| SCHEMBL18790097 | 1.00 | CCR5 (0.40) | CCR5KMT2APREPHCRTR1HCRTR2 | |
| SCHEMBL2579732 | 0.99 | CCR5 (0.39) | CCR5KMT2APREPHCRTR1HCRTR2 | |
| SCHEMBL2563376 | 0.98 | CCR5 (0.40) | CCR5KMT2APREPHCRTR1HCRTR2 | |
| SCHEMBL20971890 | 0.94 | CCR5 (0.35) | CCR5KMT2APREPHCRTR1HCRTR2 | |
| SCHEMBL20971889 | 0.94 | PREP (0.36) | CCR5KMT2APREPHCRTR1HCRTR2 | |
| SCHEMBL3628772 | 0.93 | CCR5 (0.38) | CCR5KMT2APREPHCRTR1HCRTR2 | |
| SCHEMBL3343277 | 0.93 | CCR5 (0.38) | CCR5KMT2APREPHCRTR1HCRTR2 | |
| SCHEMBL26006626 | 0.92 | CCR5 (0.40) | CCR5KMT2APREPHCRTR1HCRTR2 | |
| SCHEMBL26006228 | 0.92 | CCR5 (0.40) | CCR5KMT2APREPHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339541-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250236897-A1 | PROCESSES FOR PREPARATION OF AVACOPAN AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2025-07-24 | — | — | US | disclosed |
| US-20250213699-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2025-07-03 | — | — | US | disclosed |
| US-12290568-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-12280116-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20240424108-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-12-26 | — | — | US | disclosed |
| EP-4479546-A2 | PROCESSES FOR PREPARATION OF AVACOPAN AND INTERMEDIATES THEREOF | Teva Pharmaceuticals International GmbH (CH) | 2024-12-25 | — | — | EP | disclosed |
| US-12128106-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| US-20240307546-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| US-12076408-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-20130172347-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2013-07-04 | — | — | US | disclosed |
| US-20130172347-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2013-07-04 | — | — | US | disclosed |
| US-8445515-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| EP-2585064-A1 | C5AR ANTAGONISTS | ChemoCentryx, Inc. (US) | 2013-05-01 | — | — | EP | disclosed |
| WO-2011163640-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| US-20110275639-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275639-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20100311753-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| WO-2010075257-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160320-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339541-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | ASGR1, ENGASE, FCGR2A | CCR5 1571/4885KMT2A 4789/4885PREP 465/4885 |
| US-20100160320-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | CCR5 78/4885KMT2A 4442/4885PREP 597/4885 |
| US-20250236897-A1 | PROCESSES FOR PREPARATION OF AVACOPAN AND INTERMEDIATES THEREOF | DHPS, VARS1, AGPS | CCR5 3118/4885KMT2A 2279/4885PREP 261/4885 |
| US-20240424108-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | ASGR1, ENGASE, FCGR2A | CCR5 1571/4885KMT2A 4789/4885PREP 465/4885 |
| US-20110275639-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | CCR5 78/4885KMT2A 4442/4885PREP 597/4885 |
| US-20250213699-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | ASGR1, ENGASE, FCGR2A | CCR5 1571/4885KMT2A 4789/4885PREP 465/4885 |
| US-20100311753-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | CCR5 78/4885KMT2A 4442/4885PREP 597/4885 |
| US-12076408-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | CCR5 1571/4885KMT2A 4789/4885PREP 465/4885 |
| US-20130172347-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | CCR5 78/4885KMT2A 4442/4885PREP 597/4885 |
| US-12128106-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | CCR5 1571/4885KMT2A 4789/4885PREP 465/4885 |
| US-12290568-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | CCR5 1571/4885KMT2A 4789/4885PREP 465/4885 |
| US-12280116-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | CCR5 1571/4885KMT2A 4789/4885PREP 465/4885 |
| US-20240307546-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | ASGR1, ENGASE, FCGR2A | CCR5 1571/4885KMT2A 4789/4885PREP 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.